Using Glucose Sensors to Study Insulin Sensitivity in Diabetes and Fatty Liver Disease
Studies how well glucose sensors can measure insulin sensitivity in adults with diabetes or MASLD.
Plain-language title generated from the registry record
Registry title: RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGM
Key facts
- Where
- Singapore, SingaporeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Source: NCT07861191, who can take part
Where in Singapore
- MD6, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599Singapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National University Health System, Singapore
- Trial code
- NCT07861191
- Record updated
- 6 October 2026
- Original description
The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders. Building on findings from Project RESET, this study aims to develop and validate a continuous glucose monitoring (CGM)-based approach for assessing insulin sensitivity.Read full original descriptionShow less
RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGM
The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders. Building on findings from Project RESET, this study aims to develop and validate a continuous glucose monitoring (CGM)-based approach for assessing insulin sensitivity.
Inclusion: Adults aged between 21 and 70 years (including 70 yrs old) at the time of screening; Able to speak and understand English; No past history of acute myocardial infarction (heart attack), stroke or heart failure; Able to understand and voluntarily provide written informed consent prior to any study specific procedures; No current diagnosis of type 1 or type 2 diabetes, and not taking glucose-lowering medications; Willing and able to comply with all scheduled study procedures.
Exclusion: Known diagnosis of diabetes mellitus (type 1 or type 2), or use of antidiabetic medication; Known history of liver disease or abnormal liver function deemed clinically significant by the investigator who is a medical doctor; Known allergy or intolerance to CGM adhesives or inability to comply with CGM sensor placement, or; Any medical, psychiatric, or social condition that, in the opinion of the investigator, would interfere with the participant's ability to adhere to study procedures or would pose additional risk; Current or recent (within 3 months) use of medications known to affect glucose, including but not limited to corticosteroids; Renal impairment, defined as eGFR ≤ 60mL/min/1.73m\^2; Known pregnancy, plans to become pregnant during the study period, or currently breastfeeding, or; Participation in another interventional clinical trial within the past 3 months.